WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries.
- Read more about WHO recommends Pfizers COVID-19 pill
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/who-recommends-pfizers-covid-19-pill
No comments:
Post a Comment